Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline
- PMID: 28500192
- PMCID: PMC5429051
Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline
Abstract
Objective: To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes.
Methods: Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process included the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, with a detailed evidence review in in-person, telephone, and online meetings. Uniquely, the guideline development process included a systematic review of PPI deprescribing trials and examination of reviews of the harm of continued PPI use. Narrative syntheses of patient preferences and resource-implication literature informed recommendations. The team refined guideline content and recommendation wording through consensus and synthesized clinical considerations to address common front-line clinician questions. The draft guideline was distributed to clinicians and then to health care professional associations for review and revisions made at each stage. A decision-support algorithm was developed in conjunction with the guideline.
Recommendations: This guideline recommends deprescribing PPIs (reducing dose, stopping, or using "on-demand" dosing) in adults who have completed a minimum of 4 weeks of PPI treatment for heartburn or mild to moderate gastroesophageal reflux disease or esophagitis, and whose symptoms are resolved. The recommendations do not apply to those who have or have had Barrett esophagus, severe esophagitis grade C or D, or documented history of bleeding gastrointestinal ulcers.
Conclusion: This guideline provides practical recommendations for making decisions about when and how to reduce the dose of or stop PPIs. Recommendations are meant to assist with, not dictate, decision making in conjunction with patients.
Copyright© the College of Family Physicians of Canada.
Figures
Comment in
-
Approach to GERD.Can Fam Physician. 2017 Aug;63(8):595. Can Fam Physician. 2017. PMID: 28807948 Free PMC article. No abstract available.
Similar articles
-
Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.Can Fam Physician. 2018 May;64(5):339-351. Can Fam Physician. 2018. PMID: 29760253 Free PMC article.
-
Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline.Can Fam Physician. 2018 Jan;64(1):17-27. Can Fam Physician. 2018. PMID: 29358245 Free PMC article. Review.
-
Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline.Can Fam Physician. 2017 Nov;63(11):832-843. Can Fam Physician. 2017. PMID: 29138153 Free PMC article.
-
Self-efficacy for deprescribing: A survey for health care professionals using evidence-based deprescribing guidelines.Res Social Adm Pharm. 2018 Jan;14(1):18-25. doi: 10.1016/j.sapharm.2017.01.003. Epub 2017 Jan 28. Res Social Adm Pharm. 2018. PMID: 28214150
-
AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.Gastroenterology. 2022 Apr;162(4):1334-1342. doi: 10.1053/j.gastro.2021.12.247. Epub 2022 Feb 17. Gastroenterology. 2022. PMID: 35183361 Review.
Cited by
-
Palmitoylethanolamide (PEA) for Prevention of Gastroesophageal Inflammation: Insights from In Vitro Models.Life (Basel). 2024 Sep 24;14(10):1221. doi: 10.3390/life14101221. Life (Basel). 2024. PMID: 39459521 Free PMC article.
-
Deprescribing: What is the gold standard? Themes that characterized the discussions at the first Danish symposium on evidence-based deprescribing.Explor Res Clin Soc Pharm. 2022 Jan 7;5:100102. doi: 10.1016/j.rcsop.2022.100102. eCollection 2022 Mar. Explor Res Clin Soc Pharm. 2022. PMID: 35478500 Free PMC article.
-
Multimodal Intervention Assessing the Appropriateness of Acid Suppression Therapy is Associated With Reduced Prescriptions at the Time of Discharge for Hospitalized Inpatients.Hosp Pharm. 2023 Apr;58(2):171-177. doi: 10.1177/00185787221123212. Epub 2022 Sep 29. Hosp Pharm. 2023. PMID: 36890948 Free PMC article.
-
Ethical Aspects of Physician Decision-Making for Deprescribing Among Older Adults With Dementia.JAMA Netw Open. 2023 Oct 2;6(10):e2336728. doi: 10.1001/jamanetworkopen.2023.36728. JAMA Netw Open. 2023. PMID: 37787993 Free PMC article. Clinical Trial.
-
Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study.Support Care Cancer. 2018 Dec;26(12):4105-4113. doi: 10.1007/s00520-018-4281-3. Epub 2018 Jun 4. Support Care Cancer. 2018. PMID: 29869294 Free PMC article.
References
-
- Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16(9):e228–34. - PubMed
-
- Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol. 2009;104(Suppl 10):S27–32. Errata in: Am J Gastroenterol 2009;104(4):1072;Am J Gastroenterol 2009;104(Suppl 2):S39. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical